Purpose: To evaluate the clinical efficacy and the clinical and histopathologic tolerance of a new acrylic tissue adhesive (ADAL-2) versus 8/0 polyglactin sutures (Vicryl<sup>®</sup>) for its use in conjunctival surgery. Method: Experimental study performed on New Zealand albino rabbits. The animals were divided into two groups. Surgery consisted of a conjunctival peritomy of 8 mm in the superior limbus followed by extensive subconjunctival dissection and creation of a flap by two radial cuts. The conjunctiva was then attached to the limbus again by the proposed acrylic tissue adhesive (ADAL-2) or 8/0 polyglactin suture depending on the group. Clinical efficacy of the closure of the conjunctival wound, either with adhesives or sutures, and the clinical and histopathologic tolerance were also evaluated 1, 7, 28 and 42 days after surgery. Results: Both conjunctival surgical closure methods were found to be equal in efficacy concerning their ability to fix the conjunctiva to the limbus. There were no significant clinical and histopathologic tolerance differences between the new tissue adhesive investigated (ADAL-2) and 8/0 polyglactin sutures (Vicryl). Histopathology showed no presence of the adhesive 28 days postoperatively. Conclusions: ADAL-2 tissue adhesive is an efficient conjunctival closure method, very well tolerated by the ocular surface. Its sealing efficiency and its tolerance are similar to 8/0 polyglactin sutures. This new acrylic adhesive has a potential as an alternative for surgical conjunctival sealing in ophthalmic surgery.